Prenatal blood tests

Learning that you are expecting a baby is one of life's most joyous moments—but it can also cause anxiety when you find out that your pregnancy is a high-risk one. Women with such risks undergo screenings to rule out disorders including Patau Syndrome (trisomy 13) and Down Syndrome (trisomy 21). As an alternative to invasive procedures such as amniocentesis, which carry a small risk of loss of the fetus, Eurofins Biomnis offers non-invasive prenatal blood tests that allow for the screening of common genetic diseases during pregnancy. The test offers detection rates that exceed 99% accuracy. By opting for non-invasive prenatal blood tests, risks of chromosomal defects can be screened early.

Most expectant parents are aware of risks for fetal genetic defects, and wonder whether disorders such as Down Syndrome can be detected—but many remain unaware of non-invasive testing options. Now, effective and safer testing methods are readily available; these include baby gender blood tests for parents who wish to know the sex of the fetus early on. Reliable and rapid, the tests can be obtained starting in the tenth week of pregnancy, and detect risks for trisomies 13, 18 and 21. And when you want to know whether it's a girl or a boy from the first trimester, a baby gender blood test is a safe way to find out.

When it comes to genetic disorder screening during pregnancy, many people assume that blood tests for Down Syndrome must be at least as complicated as traditional, invasive procedures such as amniocentesis. However, the testing kit developed by Eurofins Biomnis is remarkably simple to administer. It can be prescribed by your regular healthcare provider, and you can have the blood test taken at your physician's office or at a Eurofins Biomnis partner laboratory. With results of the blood test available in around 7 working days, NIPT by Eurofins Biomis is a risk-free form ofnon-invasive Blood tests for Down Syndrome. It has been found to reduce unnecessary invasive sampling by up to 95%.